JENA, Germany, March 12, 2026 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm that is a leader in anti-inflammatory therapeutics through its focus on the complement system, announced today that it will release its financial and operational results for the fourth quarter and the full year 2025 on March 19, 2026, prior to market opening. A conference call will not be held.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company that is pioneering anti-inflammatory treatments by leveraging its proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a potent inflammatory mediator that plays a role in the advancement of numerous inflammatory diseases. The company’s lead candidate is izicopan (INF904), an oral small molecule inhibitor that blocks C5a-induced signaling through the C5a receptor. This candidate has exhibited encouraging pharmacokinetic/pharmacodynamic (PK/PD) profiles and therapeutic promise in Phase 1 and Phase 2a clinical trials. InflaRx is advancing izicopan for several inflammatory conditions, such as hidradenitis suppurativa (HS). Additionally, the Company has created vilobelimab, a novel, intravenous, first-in-class, anti-C5a monoclonal antibody that specifically binds to free C5a. Vilobelimab has shown disease-modifying clinical efficacy and a favorable tolerability profile in various clinical studies.
InflaRx was established in 2007, and the organization maintains offices and subsidiaries in Jena and Munich, Germany, along with Ann Arbor, MI, USA. More information can be found at www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are fully owned subsidiaries of InflaRx N.V. (collectively, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Any statements that are not historical facts are considered forward-looking and are frequently identified by words like “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” and similar terms. These statements are present in several sections of this release and may pertain to our intentions, beliefs, projections, outlook, analyses, or current expectations, as well as the risks, uncertainties, and other factors detailed under the headings “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic SEC filings. These statements are made only as of the date of this press release and involve significant known and unknown risks, uncertainties, and other factors that could cause our actual results, performance, or achievements to differ substantially from those anticipated in any forward-looking statements. In light of these risks and uncertainties, you should not depend excessively on these forward-looking statements. We disclaim any obligation to update these statements, even if new information becomes available later, unless required by law.